Economic benefits for the family of inactivated subunit virosomal influenza vaccination of healthy children aged 3–14 years during the annual health examination in private paediatric offices

Economic benefits of inactivated influenza vaccines in the prevention of seasonal influenza in children

“…The vaccine evaluated was the classic inactivated vaccine in 10 studies [18][19][20][21][22][23][24][25][26][27] and the virosomal inactivated vaccine in three studies [28][29][30] (the study by Weyker 22 does not mention the vaccine evaluated: however, as the study subject is the vaccination of children aged 6 months to 18 years, it may be deduced that the vaccine considered is the classic inactivated vaccine, because the vaccination did not save money, but the cost-effectiveness ratios were very low.…”

“…The end points included were clinical in all studies included. In the studies by Esposito, 28 Navas 29 and Salleras 30 various end points were evaluated (acute respiratory processes avoided, antibiotic and antipyretic prescriptions avoided, lost days of schooling avoided in the study by Esposito, 28 and acute febrile respiratory illnesses, pediatric visits, prescription of antibiotics and antipyretics, maternal work absenteeism to care for the sick child in the study by Navas 29 from the social perspective, and the same factors plus school absenteeism in the study by Salleras et al from the family perspective). 30 The remaining studies were modeled according to disease incidence, mortality rates and reported vaccine efficacies.…”

“…The estimated vaccine efficacy varied according to the study and the end point considered, but ranged between 50% and 60% [18][19][20][21][22][23][24][25]29,30 in the prevention of clinical influenza, with the exception of the studies by Marchetti 26 and Esposito 28 in which the estimate was lower. In the studies by Esposito 28 and Pisu, 21 the efficacy was estimated by means of a controlled clinical trial and in the studies by Navas 29 and Salleras 30 by means of a prospective cohort study. The end points included were clinical in all studies included.…”

“…Studies based on controlled clinical trials 21,28 and observational cohort studies 29,30 use data from a single influenza season. Given the wide variability in the incidence of seasonal influenza from one season to another, these studies might have over-or underestimated the incidence rates.…”

Vaccination of children with a live-attenuated, intranasal influenza vaccine – analysis and evaluation through a Health Technology Assessment

“…A number of studies assess the use of LAIV as a cost-saving or cost-effective intervention [20], [21], [22], [23], [24], [25], [26], [27], [28], [29], [30], [31], [32], [33], [34], [35], [36], [37], [38], [39], [40], [41], [42], [43], [44], [45], [46], [47]. However, not all studies reach consistent results.…”